Diabetes Treatment, Part 2: Oral Agents for Glycemic Management
- 1 October 2007
- journal article
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 25 (4), 131-134
- https://doi.org/10.2337/diaclin.25.4.131
Abstract
For several reasons, oral agents are typically the first medications used in the treatment of type 2 diabetes. Because of their wide range of efficacy, safety, and mechanisms of action, it is important for clinicians to gain a broad understanding of each class of oral agents to optimize diabetes control. This article reviews the major classes of oral agents used to treat type 2 diabetes, with an emphasis on the benefits and risks of each class. It is important to note that because type 1 diabetes results from an absolute deficiency of pancreatic β-cells, most oral agents are not indicated in the treatment of patients with type 1 diabetes. Oral agents are also largely not tested or approved for use in pregnancy.Keywords
This publication has 20 references indexed in Scilit:
- A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular EventsDiabetes Care, 2007
- Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 2006
- Thiazolidinedione Use and Bone Loss in Older Diabetic AdultsJournal of Clinical Endocrinology & Metabolism, 2006
- Meta‐analysis: effect of hormone‐replacement therapy on components of the metabolic syndrome in postmenopausal womenDiabetes, Obesity and Metabolism, 2005
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- PRESERVE-βDiabetes Care, 2005
- Characterization of GLP-1 Effects on β-Cell Function After Meal Ingestion in HumansDiabetes Care, 2003
- Peroxisome Proliferator–Activated Receptor γ and Metabolic DiseaseAnnual Review of Biochemistry, 2001
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Cloning of the β Cell High-Affinity Sulfonylurea Receptor: a Regulator of Insulin SecretionScience, 1995